

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 80040

Title: Precautions before starting tofacitinib in persons with rheumatoid arthritis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00863327

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Full Professor

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: India

Manuscript submission date: 2022-09-14

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-15 14:43

Reviewer performed review: 2022-09-16 17:03

Review time: 1 Day and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this Letter, by using a table, the authors summarized precautions before starting tofacitinib, a pan-Jaks inhibitor, in patients with rheumatoid arthritis. Although the findings in the manuscript are relevant to the clinical application, there are some issues needed to be clarified as follows. 1. In the beginning of the manuscript, the authors stated that we read with interest the article by Qing-Xia Lin et al[1] where authors have reported one case report of recurrent herpes zoster (HZ) in rheumatoid arthritis (RA) patients treated with tofacitinib". Nevertheless, there was only one sentence discussing the HZ event in RA patients receiving tofacitinib therapy as follows. The incidence of herpes zoster is found to be higher with tofacitinib than in the general RA population[3]. The authors should increase the length of discussion regarding tofacitinib-related HZ in RA patients in their revised manuscript. 2. In serial No.5, authors used Mantoux test and chest X-ray to rule out latent tuberculosis. Although the WHO did not recommend to replace Mantoux test (PPD test) by interferon gamma release assay (IGRA) as a public health intervention in countries with lower income, the UK recommended that IGRA should be used to help interpret positive Mantoux test. Furthermore, prior BCG vaccination may have influence on the interpretation of Mantoux test but not IGRA. Therefore, IGRA should be also considered as a diagnostic aid in latent tuberculosis infection. 3. Please check the correctness of References No. 4 (EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update) and No. 5 (Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib). 4. In the Table1, the authors should show the full names of abbreviation like NSAIDs, DMARDs, MACEs, CBC, etc. 5. There are



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

typographical errors like “--- which take participate in ---”. It should be “--- which take part in” or “--- which participate in ---”.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 80040

Title: Precautions before starting tofacitinib in persons with rheumatoid arthritis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00863327

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Full Professor

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: India

Manuscript submission date: 2022-09-14

Reviewer chosen by: Yan-Xia Xing

Reviewer accepted review: 2022-10-31 16:33

Reviewer performed review: 2022-10-31 16:45

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

There was no Table 1 in the 80040_Auto_Edited.docx. Please attach the Table 1 in the revised manuscript.